AbbVie news - the latest biotech news from Labiotech.eu

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

AbbVie takes step forward in Europe with migraine drug

Jim Cornall — Mon, 26 Jun 2023 15:19:13 +0000

AbbVie says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CMHP) has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month. If approved, AbbVie will be the only company to offer a once daily oral […]

The post AbbVie takes step forward in Europe with migraine drug appeared first on Labiotech.eu.

Five recent advancements in Parkinson’s disease research

Roohi Mariam Peter — Thu, 13 Apr 2023 13:00:00 +0000

Named after English surgeon James Parkinson, best known for his book ‘An Essay on the Shaking Palsy’ – a clinical account on the disabling condition that causes motor impairment – Parkinson’s disease was first described as a neurological syndrome in 1817. However, ancient Indian texts and Chinese sources also chronicled what seemed to be descriptions of […]

The post Five recent advancements in Parkinson’s disease research appeared first on Labiotech.eu.

UK approval for AbbVie Crohn’s disease drug

Jim Cornall — Fri, 03 Feb 2023 08:58:07 +0000

AbbVie has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved RINVOQ (upadacitinib), a janus kinase (JAK) inhibitor, for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological agent. […]

The post UK approval for AbbVie Crohn’s disease drug appeared first on Labiotech.eu.

AbbVie bets on Anima mRNA modulators to tackle cancer

Jim Cornall — Wed, 11 Jan 2023 19:06:57 +0000

AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets in oncology and immunology. Anima Biotech will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets, providing AbbVie exclusive rights to license and further develop and commercialize the programs. “This collaboration […]

The post AbbVie bets on Anima mRNA modulators to tackle cancer appeared first on Labiotech.eu.

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Jim Cornall — Mon, 28 Nov 2022 20:41:03 +0000

Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […]

The post Deep Science Ventures and AbbVie to create companies to target inflammatory diseases appeared first on Labiotech.eu.

Gate Neurosciences emerges from stealth to tackle CNS diseases

Jim Cornall — Tue, 23 Aug 2022 15:00:06 +0000

Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […]

The post Gate Neurosciences emerges from stealth to tackle CNS diseases appeared first on Labiotech.eu.

Formulations of Arecor Therapeutics’ drug to treat inflammatory diseases granted patents

Liza Laws — Tue, 09 Aug 2022 09:44:29 +0000

Formulations of a drug that can help a number of inflammatory diseases including rheumatoid arthritis and Crohn’s disease have been issued patents by the European Patent Office (EPO). The EPO issued two patents that will protect Arecor Therapeutics’ formulations of high-concentration adalimumab until 2038. The company made the announcement today (August 9). Monoclonal antibody Adalimumab, […]

The post Formulations of Arecor Therapeutics’ drug to treat inflammatory diseases granted patents appeared first on Labiotech.eu.

Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases

Liza Laws — Tue, 02 Aug 2022 09:04:37 +0000

A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […]

The post Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases appeared first on Labiotech.eu.

Positive results for drug combination used to treat rare blood cancer

Liza Laws — Mon, 18 Jul 2022 14:59:00 +0000

Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib – a medication for the treatment of intermediate or high-risk myelofibrosis (MF) – has given positive results in a study. The data, announced by US biopharma company, AbbVie, comes from cohort 3 of a phase 2 REFINE study in Janus kinase (JAK) inhibitor naïve patients with […]

The post Positive results for drug combination used to treat rare blood cancer appeared first on Labiotech.eu.

French Juvisé buys gastro product in €400M finance deal

Liza Laws — Thu, 07 Jul 2022 09:55:10 +0000

French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie. Juvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. Pylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections. Lazard and Latham […]

The post French Juvisé buys gastro product in €400M finance deal appeared first on Labiotech.eu.

AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal

External Contributor — Thu, 11 Jun 2020 17:29:44 +0000

AbbVie and Genmab have announced a €3.4B collaboration deal that ranks as the second biggest strategic alliance in European biotech in 2020. The partners aim to commercialize three phase I-stage antibody drugs for undisclosed types of solid and liquid cancer. Upfront, the US AbbVie will pay the Danish biotech €659M, with up to €2.77B available […]

The post AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal appeared first on Labiotech.eu.

AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease

Jonathan Smith — Fri, 16 Nov 2018 17:01:04 +0000

The UK biotech Mission Therapeutics has teamed up with AbbVie to develop new drugs to treat the neurodegenerative conditions Alzheimer’s disease and Parkinson’s disease. The new collaboration aims to fund the preclinical development of drugs that inhibit proteins called deubiquitinating enzymes. Deubiquitinating enzymes modify proteins in the cell, controlling essential functions such as what the […]

The post AbbVie Enters Industry Collaboration to Fight Alzheimer’s and Parkinson’s Disease appeared first on Labiotech.eu.

French Biotech Lures Big Pharma with Fibrosis Treatments

Clara Rodríguez Fernández — Tue, 05 Sep 2017 14:28:56 +0000

This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […]

The post French Biotech Lures Big Pharma with Fibrosis Treatments appeared first on Labiotech.eu.

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

Clara Rodríguez Fernández — Thu, 13 Apr 2017 12:53:18 +0000

Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […]

The post Next-Gen Cancer Antibody Technology from Germany enters the Clinic appeared first on Labiotech.eu.

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Melanie De Almeida — Thu, 23 Mar 2017 13:39:52 +0000

Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […]

The post Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug appeared first on Labiotech.eu.

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

Melanie De Almeida — Thu, 02 Feb 2017 16:32:24 +0000

After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […]

The post Galapagos kicks off a Phase IIa trial for Cystic Fibrosis appeared first on Labiotech.eu.

One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis

Clara Rodríguez Fernández — Tue, 29 Nov 2016 14:58:56 +0000

Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […]

The post One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis appeared first on Labiotech.eu.

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Dani Bancroft — Mon, 31 Oct 2016 09:30:40 +0000

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

The post UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug appeared first on Labiotech.eu.

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

Clara Rodríguez Fernández — Wed, 05 Oct 2016 06:00:13 +0000

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

The post New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira appeared first on Labiotech.eu.